Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class.
about
Bispecific antibodies for cancer therapy: the light at the end of the tunnel?Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemiaTherapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1.Bispecific T-cell engagers for cancer immunotherapy.Are BiTEs the "missing link" in cancer therapy?The CEA/CD3-bispecific antibody MEDI-565 (MT111) binds a nonlinear epitope in the full-length but not a short splice variant of CEAAn EGFRvIII-targeted bispecific T-cell engager overcomes limitations of the standard of care for glioblastoma.T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells.Cancer therapy with bispecific antibodies: Clinical experience.Bispecific antibodies engage T cells for antitumor immunotherapy.T cell-recruiting triplebody 19-3-19 mediates serial lysis of malignant B-lymphoid cells by a single T cellToxicity management for patients receiving novel T-cell engaging therapies.Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection.Concentrations of EpCAM ectodomain as found in sera of cancer patients do not significantly impact redirected lysis and T-cell activation by EpCAM/CD3-bispecific BiTE antibody MT110.Retargeting T cells to GD2 pentasaccharide on human tumors using Bispecific humanized antibody.Redirected lysis of human melanoma cells by a MCSP/CD3-bispecific BiTE antibody that engages patient-derived T cellsLarge-Scale Purification of r28M: A Bispecific scFv Antibody Targeting Human Melanoma Produced in Transgenic Cattle.Impact of Diverse Immune Evasion Mechanisms of Cancer Cells on T Cells Engaged by EpCAM/CD3-Bispecific Antibody Construct AMG 110T-cell ligands modulate the cytolytic activity of the CD33/CD3 BiTE antibody construct, AMG 330.CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomasCharacterization of the first-in-class T-cell-engaging bispecific single-chain antibody for targeted immunotherapy of solid tumors expressing the oncofetal protein claudin 6Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemiaTargeting T cells with bispecific antibodies for cancer therapyBispecific T-Cell Engagers (BiTEs) as Treatment of B-Cell Lymphoma.Investigational immunotherapeutics for B-cell malignancies.Bispecific antibodies for cancer therapy.New antibody drug treatments for lymphoma.Update on novel monoclonal antibodies and immunoconjugates for the treatment of lymphoproliferative disorders.Antibody therapy for acute lymphoblastic leukemia.Current status of antibody therapy in ALL.Blinatumomab for the treatment of B-cell lymphoma.Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody.Harnessing T cells to fight cancer with BiTE® antibody constructs--past developments and future directions.Advances in systemic delivery of anti-cancer agents for the treatment of metastatic cancer.The preparation of VEGFR1/CD3 bispecific antibody and its specific cytotoxicity against VEGFR1-positive breast cancer cells.Translation and Clinical Development of Bispecific T-cell Engaging Antibodies for Cancer Treatment.Engineering a CD123xCD3 bispecific scFv immunofusion for the treatment of leukemia and elimination of leukemia stem cells.Targeting of cancer stem cell marker EpCAM by bispecific antibody EpCAMxCD3 inhibits pancreatic carcinoma.Solid Tumor Immunotherapy with T Cell Engager-Armed Oncolytic Viruses.Oncolytic adenovirus expressing bispecific antibody targets T-cell cytotoxicity in cancer biopsies.
P2860
Q24644083-B6339DBE-E16F-4500-B680-88E796D336EDQ26785828-2A2D2D99-4FDB-461D-A5D3-20E69B46C999Q27313856-C75359E4-A624-4BF6-A25E-61C1475188B4Q27693313-98D598A8-B09B-48DC-88C3-70968B789DC4Q28083907-46B88DE2-103D-44EB-B49F-7F7554E4E28BQ28730117-6800DD45-2D0A-42C1-A202-07A8E8B5CD2EQ33665884-CCCF46DE-8B2E-4DC8-880A-9039B746273CQ34005156-17A2A58A-0FE8-477A-A6B3-1D9C99CFF109Q34118856-2EFC676B-746F-4B24-8FC3-412575973A45Q34174334-46938AB6-B909-4062-99A1-D22DD3C5C9CAQ34227769-4CDB4B99-055C-4B21-9907-00425E4FA108Q34343346-1C87FF08-D204-4205-A7FE-72834AB7AAC4Q34517676-D2D03D0B-FFFD-4BE7-863B-5AF4B1A2DB95Q34570056-EAE224B4-60CE-4D49-99D7-75ACB802CC26Q35152029-6B753847-4A13-45EF-8843-1DFA631443AEQ35368001-FE938EBB-9ECD-49B7-A679-624D6F158B9EQ35808466-31839C8A-CA95-4A88-8ED2-C2329B330794Q35824663-E21E0ABF-A774-4231-B32B-D3CB655FA7CFQ36022539-B782C457-26AD-4518-BF16-DF67A86305A4Q36211422-4B014A53-7AF9-49A7-AFAC-D4B6800D999BQ36821083-B852E7E3-359B-4DD6-A7D3-66BC3E627CADQ36834079-D8D6607F-76B0-4AD6-ACBB-24B2034B3AE8Q37220742-F58149E6-93B5-4859-B765-B85F81AA615DQ37376659-254F2EA7-F0CA-40A6-BB9C-F9DDE208ACCAQ37667386-E845ACF5-426C-4B9D-891D-9865BE965890Q37773263-A5ECC259-F5CE-47D3-9749-3ADFD7105BC6Q37852003-9AB78850-F7D3-4B5F-A222-4CC7CCB139BAQ37913356-BBC0F67C-ACD1-4C77-93D9-D957A55BB50BQ37994136-964F7D42-E5CA-4171-AB4B-E27FED1462B7Q38266338-7556164D-4E60-4C53-A0C5-79E06DD9FF12Q38367679-445BF808-40F5-4B2C-9207-3FBF6EAD88E0Q38707896-DB32B2B4-2A4E-49C6-816B-1652EED2EA45Q38728592-2CD262BF-CCBA-4DD5-8CD8-ABBA4EA87C79Q38808823-48743A41-8BDC-4ABA-B7B3-F63E03DC5893Q39044411-42283239-388C-496E-9DE2-EE433932EA6BQ39128240-B30E9B36-F790-4112-A5A8-1DBD4893FF01Q39323781-86D1C305-B746-46A8-837E-A184F4CB140CQ39733328-E632C1EC-1238-444C-BABC-E1688404B6B9Q40043393-D9EF72F1-9753-4C44-8222-F1F94464D9AFQ40152125-3AE58C1F-8BEA-481A-8D1D-0CEF6191EFE4
P2860
Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class.
description
2007 nî lūn-bûn
@nan
2007 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Strictly target cell-dependent ...... constructs of the BiTE class.
@ast
Strictly target cell-dependent ...... constructs of the BiTE class.
@en
Strictly target cell-dependent ...... constructs of the BiTE class.
@nl
type
label
Strictly target cell-dependent ...... constructs of the BiTE class.
@ast
Strictly target cell-dependent ...... constructs of the BiTE class.
@en
Strictly target cell-dependent ...... constructs of the BiTE class.
@nl
prefLabel
Strictly target cell-dependent ...... constructs of the BiTE class.
@ast
Strictly target cell-dependent ...... constructs of the BiTE class.
@en
Strictly target cell-dependent ...... constructs of the BiTE class.
@nl
P2093
P1476
Strictly target cell-dependent ...... constructs of the BiTE class.
@en
P2093
Bernd Schlereth
John Lumsden
Jörg Volkland
Klaus Brischwein
Larissa Parr
Mathias Locher
Matthias Klinger
Patrick A Baeuerle
Peter Kiener
Peter Kufer
P304
P356
10.1097/CJI.0B013E318156750C
P577
2007-11-01T00:00:00Z